Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Primary antibodies

Anti-Ixekizumab Non-Neutralizing Recombinant Antibody (SAA2902) (AS856023)

Anti-Ixekizumab Non-Neutralizing Recombinant Antibody (SAA2902)
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody (SAA2902)
Price(USD):
Spec:
  • 50ug
  • 100ug
  • 1mg
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.AS856023
Description
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody (SAA2902) (AS856023) is a mouse monoclonal antibody detecting Ixekizumab in ELISA. Suitable for General.
Highlights
  • ●Affinity Purified — Minimal background and high purity for reliable results.
Species reactivityGeneral
ApplicationsELISA
Host speciesMouse
ClonalityMonoclonal
IsotypeIgG1
Clone IDSAA2902
Immunogen Ixekizumab
Endotoxin level < 10EU/mg
Purity >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession CAS: 1143503-69-8
Form Liquid
Storage buffer 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Background

Interleukin-17A (Ixekizumab) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites.

1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361
2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633
3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971
4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828
5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122
6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
Note For research use only.
Images
  • Anti-Ixekizumab Non-Neutralizing Recombinant Antibody (SAA2902)

    Bioactivity

    Detects Ixekizumab (Catalog No: HS856016) in indirect ELISA.

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: [email protected]

Distributor list